Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in Neurogenic Bladder
NCT02044510Phase 3Terminated
- Start
- Jul 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neurogenic bladder comparing Mirabegron with Placebo (2 arms). Primary endpoint: Urodynamic Bladder Capacity at 10 weeks. Started Jul 2014; status: terminated.
02
Drugs
mirabegron
03
Conditions
neurogenic bladder
Beyond the preview
Go deeper on NCT02044510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044510.